MARKET

EPZM

EPZM

Epizyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.72
+1.18
+4.62%
After Hours: 28.00 +1.28 +4.79% 19:59 01/17 EST
OPEN
25.86
PREV CLOSE
25.54
HIGH
27.05
LOW
25.70
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
27.05
52 WEEK LOW
8.80
MARKET CAP
2.43B
P/E (TTM)
-16.5798
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EPZM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EPZM News

  • ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
  • Zacks.15h ago
  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.15h ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About EPZM

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
More

Webull offers Epizyme Inc (EPZM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.